Prevalence of autoantibodies against autonomic receptors in patients with chronic cardiopathies
Abstract
Introduction. Chagas´ disease is the main cause of chronic myocardiopathy in Central America. The mechanisms proposed for this cardiac pathology during the chronic phase remain controversial. Several studies have detected the presence of circulating autoantibodies against β-adrenergic and cholinergic muscarinic receptors of the myocardium in patients with Chagas disease. These autoantibodies can trigger intracellular signals and modify the cardiac function during the progression of the disease.Objectives. The serological frequency of these autoantibodies was compared among patients with chronic Chagas disease, patients with other cardiopathies and healthy controls.
Materials and methods. The prevalence of autoantibodies against β-adrenergic and cholinergic muscarinic receptors was determined in four groups of Panamenian patients: 53 chagasic patients, 25 serologically negative patients with cardiac insufficiency, 25 patients with cardiac arrhythmia and 25 healthy individuals.
Results. The antibodies against autonomic receptors were more frequently observed in patients with chronic chagasic cardiomyopathy (24.5%) compared to the cardiac insufficiency group (20.0%) and the cardiac arrhythmia group (16.0%). The proportion of autoantibodies was significantly different between the groups with chronic chagasic cardiomyopathy and healthy controls (24.5% versus 0%; p=0.015). Of the 53 chronically infected chagasic patients, 48 (90%) showed some degree of cardiac dysfunction.
Conclusions. The frequency of autoantibodies against autonomic receptors is significantly increased in patients with chronic Chagas disease and in patients with other cardiopathies.
Downloads
References
1. Devera R, Fernandes O, Coura JR. Should Trypanosoma cruzi be called “cruzi” complex? A review of the parasite diversity and the potential of selecting population after in vitro culturing and mice infection. Mem Inst Oswaldo Cruz. 2003;98:1-12
2. Engman DM, Leon JS. Pathogenesis of Chagas heart disease: role of autoimmunity. Acta Trop. 2002;81:123-32.
3. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz. 2003;98:577-91.
4. Sousa OE. Anotaciones sobre la enfermedad de Chagas en Panamá. Frecuencia y distribución de Trypanosoma cruzi y Trypanosoma rangeli. Rev Biol Trop. 1972;20:167-9.
5. Nuñez JM. Enfermedad de Chagas: datos pertinentes y revisión de casos atendidos en el Hospital Santo Tomás 1955 a 1964. Arch Med Panameños. 1966;15:35-47.
6. Kierszenbaum F. Chagas’ disease and the autoimmunity hypothesis. Clin Microbiol Rev. 1999;12:210-23.
7. Chiale PA, Ferrari I, Mahler E, Vallaza MA, Elizari MV, Rosenbaum MB, et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation. 2001;103:1765-71.
8. Borda E, Pascual J, Cossio P, De La Vega M, Arana R, Sterin Borda LA. Circulating IgG in Chagas´disease which binds to beta-adrenoreceptors of myocardium and modulates their activity. Clin Exp Immunol. 1984;57:679-86.
9. Giménez L, Mitelman J, González C, Borda E, Sterin-Borda L. Anticuerpos antirreceptores autonómicos, alteraciones de la variabilidad de la frecuencia cardiaca y arritmias en sujetos con enfermedad de Chagas. Rev Arg Cardio. 2003;71:109-13.
10. Saldaña A, Samudio F, Miranda A, Herrera LM, Saavedra SP, Cáceres L, et al. Predominance of Trypanosoma rangeli infection in children from a Chagas’ disease endemic area in the west-shore of the Panama Canal. Mem Inst Oswaldo Cruz. 2005;100:729-31.
11. Vasquez JE, Krusnell J, Orn A, Sousa OE, Harris RA. Serological diagnosis of Trypanosoma rangeli infected patients. A comparison of different methods and its implications for the diagnosis of Chagas’ disease. Scand J Immunol. 1997;45:322-30.
12. Puigbo JJ, Giordano H, Iosa D. Chagas’ cadioneuropathy: cardiovascular autonomic dysfunction as the first manifestation of the disease. Inter J Angiol. 1998;7:123-9.
13. Garcia S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos-de-Carvalho AC, et al. Treatment with benznidazole during the chronic phase of experimental Chagas’ disease decreases cardiac alterations. Antimicrob Agents Chemother. 2005;49:1521-8.
14. Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenoreceptors in human idiopathic dilated cardiomiopathy. Circ Res. 1989;64:97-103.
15. Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human β1-adregenic receptors are associated with reduced cardiac function in chronic heart failure. Circulation. 1999;99:649-54.
16. Kaplan D, Ferrari I, López-Bergami P, Mahler E, Levitus G, Chiale P, et al. Antibodies to ribosomal P proteins of Trypanosoma cruzi in Chagas’ disease possess functional autoreactivity with heart tissue and differ from anti-P autoanbodies in lupus. Proc Natl Acad Sci USA. 1997;94:10301-6.
17. Ferrari I, Levin MJ, Wallukat G, Elies R, Lebegue D, Chiale P, et al. Molecular mimicry between the immunodominant ribosomal protein PO of Trypanosoma cruzi and a functional epitope on the human β1-adrenergic receptor. J Exp Med. 1995;182:59-65.
18. Joensen L, Borda E, Kohout T, Perry S, Garcia G, Sterin-Borda L. Trypanosoma cruzi antigen that interacts with the beta1-adrenergic receptor and modifies myocardial contractile activity. Mol Biochem Parasitol. 2003;127:169-77.
19. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, et al. Direct evidence for a β1-adregenic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomiopathy. J Clin Invest. 2004;113:1419-29.
20. Hyland KV, Leon JS, Daniels MD, Giafis N, Woods LM, Bahk TJ, et al. Modulation of autoimmunity by treatment of an infectious disease. Infect Immun. 2007;75:3641-50.
21. Talvani A, Rocha MO, Ribeiro AL, Borda E, Sterin-Borda L, Teixeira MM. Levels of anti-M2 and anti-beta1 autoantibodies do not correlate with the degree of heart dysfunction in Chagas’ heart disease. Microbes Infect. 2006;8:2459-64.
Some similar items:
- María Clara Echeverry, Nubia Catalina Tovar, Guillermo Mora, Presence of antibodies to cardiac neuroreceptors in patients with Chagas disease , Biomedica: Vol. 29 No. 3 (2009)
- Lorenzo Cáceres, José R. Rovira, José Calzada, Azael Saldaña, Evaluation of the toxic activity of the pyrethroid insecticides deltamethrin and lambdacyhalothrin in two Panamanian field populations of Rhodnius pallescens (Hemíptera: Reduviidae) , Biomedica: Vol. 31 No. 1 (2011)
- Lisbeth A. Hurtado, José E. Calzada, Vanesa Pineda, Kadir González, Ana María Santamaría, Lorenzo Cáceres, Coridalia Wald, Azael Saldaña, Knowledge and risk factors related to Chagas’ disease in two Panamanian communities where Rhodnius pallescens is the main vector , Biomedica: Vol. 34 No. 2 (2014)
- Andrés López-Rubio, Juan David Suaza, Charles Porter, Sandra Uribe, Gabriel Bedoya, Iván Darío Vélez, Phylogenetic signal at the Cytb-SertRNA-IG1-ND1 mitochondrial region in Anopheles (Kerteszia) neivai Howard, Dyar & Knab, 1913 , Biomedica: Vol. 37 No. Sup. 2 (2017): Suplemento 2, Entomología médica, 2017
- Ernesto Pérez-Sánchez, Raúl Montiel-Cruz, Eréndira Romero-Domínguez, Griselda Pascacio-Bermúdez, Arturo Báez-Hernández, Guadalupe Díaz del Castillo-Flores, Fabián Correa-Morales, Gonzalo Vázquez-Prokopec, Pablo Manrique-Saide, Azael Che-Mendoza, Gabriela Meneses-Ruiz , Irma López-Martínez, María Jesús Sánchez, Seroprevalence of Trypanosoma cruzi among children from Veracruz, Mexico: Epidemiological baseline for a control model based on Chagas disease active transmission , Biomedica: Vol. 44 No. 1 (2024)
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
